Huang, J. ; Covic, M. ; Huth, C. ; Rommel, M. ; Adam, J. ; Zukunft, S. ; Prehn, C. ; Wang, L. ; Nano, J. ; Scheerer, M.F. ; Neschen, S. ; Kastenmüller, G. ; Gieger, C. ; Laxy, M. ; Schliess, F.* ; Adamski, J. ; Suhre, K.* ; Hrabě de Angelis, M. ; Peters, A. ; Wang-Sattler, R.
Validation of candidate phospholipid biomarkers of chronic kidney disease in hyperglycemic individuals and their organ-specific exploration in leptin receptor-deficient db/db mouse.
Metabolites 11:89 (2021)
Biological exploration of early biomarkers for chronic kidney disease (CKD) in (pre)diabetic individuals is crucial for personalized management of diabetes. Here, we evaluated two candidate biomarkers of incident CKD (sphingomyelin (SM) C18:1 and phosphatidylcholine diacyl (PC aa) C38:0) concerning kidney function in hyperglycemic participants of the Cooperative Health Research in the Region of Augsburg (KORA) cohort, and in two biofluids and six organs of leptin receptor-deficient (db/db) mice and wild type controls. Higher serum concentrations of SM C18:1 and PC aa C38:0 in hyperglycemic individuals were found to be associated with lower estimated glomerular filtration rate (eGFR) and higher odds of CKD. In db/db mice, both metabolites had a significantly lower concentration in urine and adipose tissue, but higher in the lungs. Additionally, db/db mice had significantly higher SM C18:1 levels in plasma and liver, and PC aa C38:0 in adrenal glands. This cross-sectional human study confirms that SM C18:1 and PC aa C38:0 associate with kidney dysfunction in pre(diabetic) individuals, and the animal study suggests a potential implication of liver, lungs, adrenal glands, and visceral fat in their systemic regulation. Our results support further validation of the two phospholipids as early biomarkers of renal disease in patients with (pre)diabetes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Chronic Kidney Disease ; Diabetic Nephropathy ; High-fat-diet ; Leptin Receptor-deficient Mouse ; Liver ; Lungs ; Metabolomics ; Prediabetes And Type 2 Diabetes ; Reduced Kidney Function
Keywords plus
Language
english
Publication Year
2021
Prepublished in Year
HGF-reported in Year
2021
ISSN (print) / ISBN
2218-1989
e-ISSN
2218-1989
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 11,
Issue: 2,
Pages: ,
Article Number: 89
Supplement: ,
Series
Publisher
MDPI
Publishing Place
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30202 - Environmental Health
30201 - Metabolic Health
90000 - German Center for Diabetes Research
30205 - Bioengineering and Digital Health
30505 - New Technologies for Biomedical Discoveries
Research field(s)
Genetics and Epidemiology
Enabling and Novel Technologies
PSP Element(s)
G-504091-003
G-504000-006
G-505600-003
G-501900-062
G-503891-001
G-505300-002
G-504000-010
G-500600-001
G-504090-001
G-504091-004
G-504000-002
A-630710-001
Grants
Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ
State of Bavaria
Helmholtz Zentrum Munchen-German Research Center for Environmental Health - German Federal Ministry of Education and Research (BMBF)
Biomedical Research Program funds at Weill Cornell Medical College in Qatar - Qatar Foundation
EIT, a body of the European Union
EIT Health
iPDM-GO "Integrated Personalized Diabetes Management goes Europe" innovation project
Copyright
Erfassungsdatum
2021-03-03